Anthem Biosciences IPO Subscription started on Monday, July 14, and will close on July 16, 2025, as scheduled. The price band is set at ā¹540 to ā¹570 per share with a face value of ā¹2.
Anthem Biosciences IPO Subscription Status
Anthem Biosciences IPOĀ subscribed over 3.48x on its Second day till 05.00 PM on 15th July.
- Anthem Biosciences IPO subscription QIB investors portion is 0.62x times, while NII subscribers subscribed 10.42x times, and RII investors subscribed 2.21x times.
- The company has received bids for 14,51,62,680 shares against 4,17,50,321 shares on offer on the Second day.
- Anthem Biosciences IPO subscribed over 3.48x on day 2.
- Anthem Biosciences IPO subscribed over 0.77x on day 1.
About Anthem Biosciences IPO
Anthem Biosciences Limited, founded in 2006, is one of the growing innovation-driven and technology-focused Contract Research, Development and Manufacturing Organizations (āCRDMOā) with end-to-end operations covering drug discovery, development, and manufacturing. Anthem Biosciences is one of the few companies in India with integrated capabilities in New Chemical Entities (NCE) and New Biological Entities (NBE) throughout drug discovery, development, and commercial manufacturing.
Anthem Biosciences is a one-stop service provider engaged in serving a wide range of customers, including emerging biotech companies and large pharmaceutical firms around the world. The company is involved in the manufacturing of specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. The company has supplied to over 150 customers, from small biotech to large pharmaceutical companies, as of March 31, 2024. Currently, the company has a team of 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, and chemical engineers.
Anthem Biosciences IPO Company Financial Report
The company reported revenue of ā¹1,930.29 crores in 2025 against ā¹1,483.07 crores in 2024. The company reported a profit of ā¹451.26 crores in 2025 against a profit of ā¹367.31 crores in 2024.
Anthem Biosciences IPO GMP:
Anthem Biosciences IPO GMPĀ was ā¹117 as of Tuesday, July 15th, 2025. That indicates the IPO is trading at ā¹687 with a ā¹117 premium in the grey market against the issue price of ā¹570.
